{
    "id": 4680,
    "name": "breast metaplastic carcinoma",
    "source": "DOID",
    "definition": "A breast carcinoma that represents a mixed group of malignant neoplasms characterized by the histologic presence of two or more cellular types. [url:http\\://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2013-0358-RS?code=coap-site, url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388429/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4680",
    "evidence": [
        {
            "id": 15872,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Buparlisib (BKM120) in combination with Taxol (paclitaxel) resulted in a durable partial response in a patient with breast metaplastic carcinoma harboring PIK3CA H1047R, with a total response period of 70 weeks and an overall survival of 42 months (PMID: 30577988).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 1545,
                "therapyName": "Buparlisib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 4680,
                "name": "breast metaplastic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13879,
                    "pubMedId": 30577988,
                    "title": "PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30577988"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}